News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Appoints Mark Kaufmann to Chief Business Officer
FREMONT, CALIFORNIA. AUGUST 31, 2011 – Ardelyx, Inc. today announced it has appointed Mr. Kaufmann to the newly created position of Chief Business Officer. Mr. Kaufmann’s role will include business and corporate development, licensing, and strategic planning. Mr.
View HTML
Toggle Summary Ardelyx, Inc. Closes $30M Series B Financing
Ardelyx, Inc. Closes $30M Series B Financing   FREMONT, CALIFORNIA. AUGUST 31, 2011 – Ardelyx, Inc. today announced it has closed a Series B preferred stock financing of $30.0 million. Participating in the Series B financing are previous investors in the Company, NEA, CMEA and certain
View HTML
Toggle Summary "Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
"Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
View HTML
Toggle Summary Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012
RDX5791, A NON-SYSTEMIC NHE3 INHIBITOR, ALONE OR IN COMBINATION WITH ENALAPRIL, PREVENTS CARDIOVASCULAR AND RENAL DYSFUNCTION IN SALT FED RATS WITH RENAL INSUFFICIENCY Andrew G. Spencer1, Marc Navre1, Craig F. Plato2, Kristin M. Joly2, Kevin Ida2, Eric D. Labonte1, Jeffrey W.
View HTML
Toggle Summary AstraZeneca and Ardelyx Announce Worldwide Licensing Deal For NHE3 Inhibitor Programme For Complications Of Renal Disease, Including Diabetes-Induced Renal Disease.
AstraZeneca and Ardelyx today announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme, including the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease  (ESRD) and chronic kidney disease
View HTML
Toggle Summary Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration with AstraZeneca
FREMONT, CALIFORNIA. JANUARY 13, 2014 – Ardelyx, Inc. today announced it has received $15 million USD from AstraZeneca (NYSE:AZN, LON:AZN), representing a development milestone that was part of the collaboration agreement the companies had previously executed.
View HTML
Toggle Summary Ardelyx Licenses NaP2b Phosphate Inhibitor Program for Kidney Disease to Sanofi in Deal Worth Up to $198 Million.
FREMONT, CALIFORNIA. FEBRUARY 24, 2014 – Ardelyx, Inc. today announced that it has licensed to Sanofi (NYSE: SNY; EURONEXT: SAN) its novel phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2). Ardelyx will receive an  undisclosed upfront payment from
View HTML
Toggle Summary Ardelyx Receives $25 Million Milestone From AstraZeneca For Commencement Of Phase 2b Clinical Trial Of Tenapanor
Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis   FREMONT, Calif., May 15, 2014/PRNewswire/--Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has
View HTML
Toggle Summary Ardelyx Announces Pricing of its Initial Public Offering
FREMONT, California – June 18, 2014 – Ardelyx, Inc.,  a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00
View HTML
Toggle Summary Ardelyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
FREMONT, Calif. , June 24, 2014 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the closing of its initial public offering of 4,928,900 shares of common stock at an initial public offering
View HTML